Home » Bio
To address the challenges of resistance to..
Maria Karlou, PhD:
University of Athens
Mentor:
Christopher Logothetis, MD
Prostate cancer diagnosis and precision medicine decisions..
Rajan Kulkarni, MD, PhD:
David Geffen School of Medicine at UCLA
Mentors:
Matthew Rettig, MD, Dino Di Carlo, PhD
Proposal Title:
Utilizing Vortex Chip for Enumeration and Determination of Single-Cell Heterogeneity of Circulating Tumor Cells in Prostate Cancer
T cells are immune cells with a..
Haydn Kissick, PhD:
The Emory Vaccine Center and the Department of Urology, Emory University
Mentors:
Martin Sanda, MD, Rafi Ahmed, PhD
Proposal Title:
Vaccination against Patient Specific Coding Mutations to Treat Prostate Cancer
The poor solubility and bioavailability of many..
Charalambos Kaittanis, PhD:
Memorial Sloan-Kettering Cancer Center
Mentors:
Jan Grimm, MD, PhD, Steven M. Larson, MD
Proposal Title:
Overcoming Drug Resistance in Advanced Prostate Cancer with Multifunctional Nanosponges
Lifestyle, guidelines, and etools to improve prostate..
Stacey Kenfield, ScD:
University of California, San Francisco
Mentor:
June Chan, ScD
Investigating the biological significance of novel recurrent..
Kalpana Kannan, PhD:
Baylor College of Medicine
Mentor:
Laising Yen, PhD and Michael Ittman, MD, PhD
Certain oncogenic molecules in prostate cancer cells..
Theodoros Karantanos, MD:
MD Anderson Cancer Center
Mentors:
Timothy Thompson, PhD and Christopher Logothetis, MD
Project Title:
The role of aerobic glycolysis in the development of castrate resistant prostate cancer
New therapeutic targets and prognostic biomarkers for..
Vishal Kothari, PhD:
University of Michigan
Mentors:
Arul Chinnaiyan, MD, PhD; Felix Feng, MD
Proposal Title:
Investigating DNAPK as a Therapeutic Target and a Prognostic Biomarker in Castration-Resistant Prostate Cancer
The emergence of treatment-resistant prostate cancer (CRPC)..
Won Kim, MD:
University of California, San Francisco
Mentors:
Charles Ryan, MD; Eric Small, MD
Proposal Title:
Dissecting Variant Androgen Signaling Phenotypes to Guide Treatment Selection in Abiraterone Acetate and Enzalutamide-Resistant Prostate Cancer
View All Board Members here.
Chief Executive Officer
Chief Medical Officer
Co-Founder
Convergent Therapeutics
Philip Kantoff, MD received his undergraduate degree..